Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail.
Recommended Childhood and Adolescent Immunization Schedule --- United States, 2006
Harmonized Childhood and Adolescent Immunization Schedule, 2006
The Advisory Committee on Immunization Practices (ACIP) periodically reviews the recommended childhood
and adolescent immunization schedule to ensure that the schedule is current with changes in vaccine formulations
and reflects revised recommendations for the use of licensed vaccines, including those newly licensed. The recommendations
and format of the childhood and adolescent immunization schedule and catch-up schedule for January--December 2006
were approved by ACIP, the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians
(AAFP) (Figure and Table).
The changes to the previous childhood and adolescent
immunization schedule, published January 2005
(1), are as follows:
The importance of the hepatitis B vaccine (HepB) birth dose has been emphasized. Vaccination of infants born
to hepatitis B surface antigen (HBsAg)-negative mothers can be delayed in rare circumstances, but only if a physician's
order to withhold the vaccine and a copy of the mother's original HBsAg-negative laboratory report are documented in
the infant's medical record. Administering four doses of HepB is permissible (e.g., when combination vaccines
are administered after the birth dose); however, if monovalent HepB is used, a dose at age 4 months is not needed. For
infants born to HBsAg-positive mothers, testing for HBsAg and antibody to HBsAg after completion of the vaccine series
should be conducted at age 9--18 months (generally at the next well-child visit after completion of the vaccine series).
A new tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine recommended by ACIP for
adolescents (Tdap adolescent preparation) was approved by the Food and Drug Administration (FDA) on May 5, 2005, for use in
the United States. Tdap is recommended for adolescents aged 11--12 years who have completed the recommended
childhood diphtheria and tetanus toxoids and pertussis/diphtheria and tetanus toxoids and acellular pertusis
(DTP/DTaP) vaccination series and have not received a tetanus and diphtheria toxoids (Td) booster dose. Adolescents aged 13--18
years who missed the age 11--12-year Td/Tdap booster dose should also receive a single dose of Tdap if they have
completed the recommended childhood DTP/DTaP vaccination series. Subsequent Td boosters are recommended every 10 years
(2).
Meningococcal conjugate vaccine (MCV4), approved by FDA on January 14, 2005, should be administered to
all children at age 11--12 years as well as to unvaccinated adolescents at high school entry (age 15 years). Other
adolescents who wish to decrease their risk for meningococcal disease may also be vaccinated. All college freshmen living
in dormitories should also be vaccinated with MCV4 or meningococcal polysaccharide vaccine (MPSV4). For prevention
of invasive meningococcal disease, vaccination with MPSV4 for children aged 2--10 years and with MCV4 for older
children in certain high-risk groups is recommended
(3).
Influenza vaccine is now recommended for children aged
>6 months with certain risk factors, which now
specifically include conditions that can compromise respiratory function or handling of respiratory secretions or that can increase
the risk for aspiration (4).
Hepatitis A vaccine is now universally recommended for all children at age 1 year (12--23 months). The 2 doses in
the series should be administered at least 6 months apart.
The catch-up schedule for persons aged 7--18 years has been changed for Td; Tdap may be substituted for any dose in
a primary catch-up series or as a booster if age appropriate for Tdap. A 5-year interval from the last Td dose is
encouraged when Tdap is used as a booster dose.
Vaccine Information Statements
The National Childhood Vaccine Injury Act requires that health-care providers provide parents or patients with copies
of Vaccine Information Statements before administering each dose of the vaccines listed in the schedule. Additional
information is available from state health departments and from CDC at
http://www.cdc.gov/nip/publications/vis.
Detailed recommendations for using vaccines are available from package inserts, ACIP statements on specific vaccines,
and the 2003 Red Book (5). ACIP statements for each recommended childhood vaccine are available at the
CDC National Immunization Program website at
http://www.cdc.gov/nip/publications/acip-list.htm. In addition, guidance
for obtaining and completing a Vaccine Adverse Event Reporting System form is available at
http://www.vaers.hhs.gov or
by telephone, 800-822-7967.
CDC. ACIP recommends adolescent vaccination for tetanus, diphtheria and pertussis vaccine. Atlanta, GA: US Department of Health and
Human Services, CDC; June 30, 2005. Available at
http://www.cdc.gov/nip/pr/pr_tdap_jun2005.htm.
American Academy of Pediatrics. Active and passive immunization. In: Pickering LK, ed. 2003 red book: report of the Committee on
Infectious Diseases. 26th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2003.
The Recommended Childhood and Adolescent Immunization Schedule and the Catch-up Childhood and Adolescent Immunization Schedule have been approved by the Advisory
Committee on Immunization Practices, the American Academy of Pediatrics, and the American Academy of Family Physicians. The standard
MMWR footnote format has been modified for publication
of this schedule.
Suggested citation: Centers for Disease Control and Prevention. Recommended childhood and adolescent immunization schedule---United States, 2006. MMWR 2005;54 (Nos.
51&52):Q1--Q4.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of
Health and Human Services.References to non-CDC sites on the Internet are
provided as a service to MMWR readers and do not constitute or imply
endorsement of these organizations or their programs by CDC or the U.S.
Department of Health and Human Services. CDC is not responsible for the content
of pages found at these sites. URL addresses listed in MMWR were current as of
the date of publication.
Disclaimer
All MMWR HTML versions of articles are electronic conversions from ASCII text
into HTML. This conversion may have resulted in character translation or format errors in the HTML version.
Users should not rely on this HTML document, but are referred to the electronic PDF version and/or
the original MMWR paper copy for the official text, figures, and tables.
An original paper copy of this issue can be obtained from the Superintendent of Documents,
U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800.
Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to
mmwrq@cdc.gov.
